acute coronary syndrome. 13 Although it is necessary to identify peak values of biomarkers for precise quantification of the injured myocardial mass, it would be clinically useful to know how precisely the first single-point data obtained soon after patient arrival at an emergency room can predict the severity of myocardial injury, and to determine differences between the characteristics of biomarkers.
This study was designed to clarify whether the first single-point data of biomarkers in patients with suspected acute coronary syndrome can predict the severity of the injured myocardium quantified by 2 kinds of scintigraphic techniques using perfusion and metabolic tracers, by comparing with the peak values of biomarkers. The present study cohort consisted of consecutive patients presenting with acute chest pain suggestive of acute coronary syndrome at an emergency room and in whom troponin-T (TnT), H-FABP, myocardial-bound creatine kinase (CK-MB) and myoglobin were quantitatively evaluated.
Social Insurance General Hospital, Sapporo; Shin-nittetsu Muroran General Hospital, Muroran; Sapporo Junkanki Clinic, Sapporo; and Teine Keijinkai Hospital, Sapporo. Entry criteria were: (1) the presence of acute anterior, precordial, or left-sided chest pain suggestive of acute coronary syndrome based on careful history taking; (2) a clinical need to measure conventional biomarkers for the detection of myocardial injury; (3) the first blood sample for measurements of TnT, H-FABP, CK-MB and myoglobin having been obtained within 30 min after patient arrival at the emergency room; (4) no history of previous myocardial infarction or coronary revascularization; and (5) informed consent having been obtained for entry in the present study. Forty-six patients were men and 28 were women. The mean age of the subjects was 63.7±1.4 years ( Table 1) .
Final clinical diagnoses were established before discharge. The diagnosis of coronary artery disease was made by clinical history in conjunction with other clinical features, electrocardiographic changes and serum biomarkers as follows: (1) acute myocardial infarction (AMI) established by typical clinical symptoms (severe chest pain lasting for 30 min or more), ECG changes (ST-segment elevation or depression in 2 or more leads of the standard 12-lead electrocardiogram for over 30 min) and positive serum biomarkers (elevated troponin or CK-MB during the first 2 days after onset of chest pain); (2) unstable angina based on the criteria of Brawnwald et al 15 using clinical symptoms (new-onset, prolonged, worsening and/or rest angina), no ST-segment elevation and negative serum biomarkers after onset of chest pain; and (3) other types of angina established by clinical symptoms (rest or effort-induced angina), evidence of reversible ischemia on an electrocardiographic and/or scintigraphic stress test, negative serum biomarkers and an angiographic finding of coronary luminal narrowing of 75% or more or coronary spasm when necessary. The diagnosis of heart failure was made by clinical symptoms (easy fatigability, exertional dyspnea, palpitation and orthopnea) and signs (jugular vein dilatation, moist rales, S3 gallop and peripheral edema), pulmonary congestion or cardiomegaly on a chest radiograph, and impaired cardiac function with a let ventricular ejection fraction of 40% or less.
Study Protocol and Measurement of Biomarkers
The first blood sampling was performed within 30 min after patient arrival at an emergency room, and then serial samplings were performed at 6-h intervals for 48 h when indicated. All samples collected for the present study were delivered to a core laboratory in Tokyo, where biomarkers were measured using methods previously reported. 13 Briefly, serum levels of H-FABP, myoglobin and TnT, and serum CK-MB activity were measured by a 2-step direct sandwich-ELISA method with monoclonal mouse anti-human H-FABP antibodies, a radioimmunoassay (Myoglobin Kit [Daiichi] III, Daiichi Radiosiotope Co, Tokyo, Japan), an electrochemiluminescence immunoassay (EcLusys troponin T 3 stat, Roche Diagnostics Co, Tokyo, Japan), and an immunoinhibition assay (Merk Auto CK-MB, Kanto Chemical Co, Tokyo, Japan), respectively. According to the manufacturers' manuals, the cut-off levels of serum myoglobin and TnT concentrations and serum CK-MB activity were 60 ng/ml, 0.1 ng/ml and 25 U/L, respectively. The lower limit of H-FABP detection was 1.25 ng/ml, and a cut-off level to define a significant elevation was set at 6.2 ng/ml. 10, 13 During convalescence (nearly 4 weeks) after admission, myocardial perfusion imaging using 99m Tc-tetrofosmin or 99m Tc-sestamibi (600-740 MBq) and myocardial fatty acid imaging using 123 I--methyl-p-iodophenyl-pentadecanoic acid (BMIPP) (111 MBq) were performed at rest, separately within an interval of a few days. Following planner imaging, single-photon emission computed tomography (SPECT) data were collected at 5-degree increments for 30 s per increment during a 180-or 360-degree rotation using a rotating gamma camera equipped with a high-resolution, parallel-hole collimator, and were stored in a 64×64 word matrix nuclear medicine computer system. Following reconstruction of transverse tomograms by a filtered back projection algorithm, short-axis, vertical long-axis, and horizontal long-axis tomograms were obtained. Myocardial uptake of perfusion tracer and BMIPP was scored visually by 2 nuclear cardiologists with semi-quantitative visual analysis using a 5-point, 20-segment model (Fig 1) : 0= normal, 1= slight reduction, 2= moderate reduction, 3= severe reduction, and 4= absence. Summed rest score was calculated in both SPECT images. Abnormality was defined as when there was at least 1 segment with a score of 3 or more or when there were 2 segments with a score of 2 or more.
Statistics
Statistical values are shown as mean ±1 standard deviation. Comparison of mean values in 2 groups was made using the unpaired Student's t-test, and prevalence was compared using the chi-squared test. Correlations among integrated tracer defect (summed scores) and peak values of biomarkers were analyzed by using linear regression analysis with standard errors of the estimate and a 95% confidence interval, and by using Spearman's rank correlation test because of non-parametric features of scintigraphic scores. A p-value less than 0.05 was considered to be statistically significant. These analyses were performed Resting myocardial perfusion and -methyl-p-iodophenyl-pentadecanoic acid (BMIPP) tomograms of patients with acute myocardial infarction. (A) A 58-year-old male with anterior wall infarction whose initial heart-type fatty acid-binding protein (H-FABP), troponin-T (TnT), myocardial-bound creatine kinase (CK-MB) and myoglobin levels were 400 ng/ml, 21.9 ng/ml, 230.4 IU/L and 2,300 ng/ml, respectively; (B) A 59-year-old male with inferior wall infarction whose initial H-FABP, TnT, CK-MB and myoglobin levels were 22 ng/ml, 0.17 ng/ml, 7.3 IU/L and 97 ng/ml, respectively. Table 1 shows the final diagnoses of the 74 patients: 41 patients had AMI, 13 had unstable angina pectoris, 3 had effort angina pectoris, 3 had effort and rest angina pectoris, 4 had spastic angina, and 5 had heart failure. The remaining 5 had non-cardiac diseases; 1 patient had pulmonary embolism and 4 patients had atypical chest pain without definitive cardiac disease. Coronary angiography was performed in 69 of 74 patients. Thirty-two of 41 patients with AMI underwent percutaneous transluminal coronary angioplasty (PTCA) at an acute stage. In 66 (89.2%) of 74 patients, coronary arteries were patent at the first blood sampling.
Results
Mean left ventricular ejection fraction was 52±2%. Perfusion imaging was performed in 68 patients with an onset-to-perfusion SPECT imaging interval of 29±6 days and BMIPP imaging in 60 patients with an onset-to-SPECT imaging interval of 23±5days. The remaining patients, however, did not undergo scintigraphic imaging because of the patients' inconvenience or early discharge. The median period between onset of chest pain and first blood sampling was 5.8 h, and first blood samples in 85% of the patients were obtained within 72 h. The mean interval between onset of chest pain and first blood sampling of each diagnosis were as follows: patients with AMI: 35.1±144.0 h; patients with unstable angina pectoris: 32.6±46.7 h; patients with effort angina pectoris: 855±1,357 h; patients with spastic angina: 75.8±51.0 h; patients with non-cardiac disease: 5.3±4.5 h. The mean interval of AMI and non-AMI were 35.1±144.0 vs 206±661 h, respectively (p=0.118). Table 2 . Table 2 .
with unstable angina but no ST-segment elevation infarction, 4 (31%) patients had positive H-FABP, 8 (62%) had positive myoglobin, 2 (15%) had TnT and all had positive CK-MB, while perfusion defect and metabolic damage were observed in 5 and 7 patients, respectively. In the present study, 41 patients arrived at the hospital within 12 h. The accuracy of H-FABP, CK-MB, TnT, and myoglobin for perfusion SPECT were 78.4, 48.6, 62.2, and 78.4%, respectively, for patients presenting within 0-12 h from onset; 75.9, 55.2, 65.5, and 72.4%, respectively, for those presenting within 2-12 h from onset; and 64.7, 58.8, 64.7, and 58.8%, respectively, for those presenting within 4-12 h from onset. H-FABP and myoglobin had higher sensitivity and specificity in early phase than CK-MB or TnT. Tables 2 and 3 show results of linear regression analysis and Spearman's rank correlation test using the first singlepoint or peak data of biochemical markers and abnormalities on myocardial perfusion or BMIPP images. Although the first single-point data of CK-MB, TnT and myoglobin significantly correlated with summed rest scores of perfusion and BMIPP images, peak values of H-FABP, CK-MB, TnT and myoglobin had closer correlations with scintigraphic abnormalities. Overall, the first single-point and peak values of TnT level more closely correlated with extents of perfusion and BMIPP abnormalities than did those of H-FABP or CK-MB (Tables 2 and 3 ): y=13.0+0.61x, r=0.503, p=0.0004 for myocardial perfusion and y=16.7+0.72x, r=0.538, p=0.0002 for BMIPP (Fig 4) . When only patients in whom the first blood sampling had been performed within 24 h after onset of acute chest pain were considered for this analysis, better correlations between peak values of biomarkers and defect scores of myocardial perfusion or BMIPP images were found (Table 4) ; correlation coefficients were 0.414 and 0.421 for H-FABP, 0.597 and 0.574 for CK-MB, 0.626 and 0.626 for TnT, and 0.641 and 0.565 for myoglobin, respectively. Biomarker levels in 8 patients with AMI who did not undergo PTCA were significantly lower than in patients in whom the coronary artery was patent. In the 8 patients, the interval from onset of chest pain to first blood sampling was longer than in other patients.
Discussion

Biomarkers for the Detection of Myocardial Injury
The results of the present study revealed that biomarkers have high positive predictive values (80-100%) but low negative predictive values (15-41%) for the detection of scintigraphic defects of myocardial perfusion and fatty acid uptake by using the first single-point data on arrival. CK-MB and TnT, however, had lower positive rates (22% for CK-MB and 27% for TnT) than did H-FABP (61%) and myoglobin (68%), resulting in greater sensitivities of H-FABP and myoglobin (75-80%) than those of CK-MB and TnT (29-35%). Among the biomarkers, therefore, H-FABP had better overall diagnostic values for the detection of myocardial injury, including high positive predictive values (84-91%), high sensitivities (75-77%) and better negative predictive values (nearly 40%). Myoglobin is less specific than is H-FABP or TnT. Troponin is established as a biomarker and is widely used but less sensitive at a very acute phase of myocardial injury (within 6 h from the onset of symptoms). 1,2 Our recent study showed that H-FABP has greater diagnostic value in patients with suspected acute coronary syndrome than does TnT, CK-MB or myoglobin within 6 h following onset of acute chest pain rather than at a later stage. 13 This is because H-FABP is a small soluble protein that is abundantly present in the cytoplasm and can be rapidly released into circulation shortly after the onset of sarcolemmal injury.
Low negative predictive values of the 4 biomarkers indicate high false-negative results of first single data, suggesting the necessity of serial measurements of biomarkers for better diagnosis of myocardial injury when negative results are obtained. Conversely, positive biomarkers and negative scintigraphic abnormality was observed in patients with unstable angina but with no ST-segment elevation infarction. Minimal myocardial injury or micronecorosis can be identified by biomarkers but not by an imaging technique because of limited SPECT spatial resolution. Delayed contrast-enhanced magnetic resonance may be a promising imaging tool to identify subendocardial infarction or a small infarct area because of a high spatial resolution. On the other hand, positive predictive values were reduced by false-positive results due to a non-ischemic or non-cardiac cause of elevation in biomarkers observed in patients with acute myocarditis, acute heart failure or impaired renal function. 10, 13 
Biomarkers for the Prediction of Injured Myocardial Mass
Scintigraphic techniques have contributed to the quantification of injured myocardial mass. A resting myocardial perfusion defect during convalescence reflects myocardial necrosis that is closely related to left ventricular ejection fraction and mortality rate. [15] [16] [17] [18] [19] [20] Although patients with biomarker-positive but SPECT-negative myocardial injury have preserved left ventricular systolic function, their longterm prognosis has not been determined. In this study, myocardial metabolic injury was also evaluated by fatty acid imaging with BMIPP because myocardial fatty acid metabolism is more susceptible to ischemia and could be a better marker of myocardial injury than myocardial perfusion abnormality. [21] [22] [23] [24] Cardiac fatty acid metabolism is impaired even in the myocardium that survives after an acute ischemic event, and impaired BMIPP uptake is closely related to intracellular high-energy phosphate depletion due to ischemia 22 and to regional wall motion abnormality. 23, 24 The present study showed that the first single-point troponin data on arrival can reflect injured myocardial mass, although the accuracy is limited and peak values of biomarkers more closely correlated with scintigraphically assessed injured mass than did the first singlepoint data. This is because the accuracy depends not only on timing of patient arrival at an emergency room after onset of chest pain, but also on the process by which biomarkers are released into the blood following acute ischemic injury. Overall, TnT had better correlations with myocardial perfusion and metabolic defect sizes among the biomarkers. Measurement of troponin level enables prediction of the risk of mortality in patients with acute coronary syndrome. [1] [2] [3] [4] [5] [6] [7] Recent studies have shown that an early or sustained elevation in H-FABP level in patients presenting with chest pain at an emergency department could indicate unfavorable clinical outcomes. 13, 14 The present study results indicate that elevated biomarkers at an early stage of chest symptoms, particularly TnT, are useful for the prediction of the severity of ischemia-induced metabolic injury and myocardial necrosis as determinants of patient prognosis. This is because viable myocardium in an area at risk assessed by cardiac fatty acid imaging or stress perfusion imaging is responsible for future cardiac events as well as infarct size. 25, 26 
Study Limitations
The false-negative results of the first single-point data on arrival indicate limitations in precise diagnosis and prediction of myocardial injury determined at convalescence. The significant but limited correlations between biomarkers and injured myocardial mass assessed by scintigraphic imaging are due to differences in large variations of timings of patient arrival, time-dependent sensitivities of biomarkers, types of myocardial injury and different process by which biomarkers are released into the circulation. Large variations of blood sampling interval are inevitable in this prospective study because the onset-to-arrival interval is dependent on patient condition and accessibility to the hospital. A large scale study using a number of patients with acute chest pain could overcome the limitations to clarify more precisely the difference in diagnostic efficacies among biomarkers of the first data obtained on patient arrival. 27 Myocardial necrosis and metabolic impairment were assessed during convalescence of acute coronary syndrome because perfusion abnormality and metabolic derangement are changeable during the first week but stabilize 2 to 4 weeks later. Quantitative data of H-FABP were obtained 24 h after blood sampling in this study. A rapid panel test for H-FABP measurement using a whole-blood sample, which was recently developed, can provide a qualitative result within 15 min, 27 as well as that for troponin. 28 Therefore, combined use of a rapid qualitative assessment and a quantitative measurement of biomarkers could contribute to early decision-making in an emergent situation and to early prediction of the severity of ischemia-induced myocardial injury. Finally, more recently noted biomarkers, such as brain natriuretic peptide, C-reactive protein and myeloperoxidase, remain to be compared to reveal early diagnostic and prognostic values in patients with suspected acute coronary syndrome.
Conclusions
Despite limited ability, the first single-point data of H-FABP on arrival at an emergency unit are useful for early detection of myocardial injury among the biomarkers currently available. Quantitative serial assessment of serum TnT level is most likely to contribute to the prediction of the size of the injured myocardium in patients presenting with acute chest pain suggestive of acute coronary syndrome. Thus, differential features among biomarkers are likely to be complementary, and suggest that the combined assessment of these markers can contribute to precise risk stratification in patients with acute chest pain in an emergency room.
